GABAB receptor ligands for the treatment of alcohol use disorder: Preclinical and clinical evidence

Frontiers in Neuroscience

Volumn , Issue 8 JUN, 2014, Pages

  Agabio, Roberta ^a   Colombo, Giancarlo ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

Alcohol use disorder; Animal models of alcohol use disorder; Baclofen; GABAB receptor; Positive allosteric modulators

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; BACLOFEN;

ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ALCOHOLISM; ALLOSTERISM; BINDING SITE; BINGE DRINKING; CLINICAL STUDY; DRINKING BEHAVIOR; HUMAN; MEDICAL RECORD REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; VERTIGO; WEAKNESS; WITHDRAWAL SYNDROME;

EID: 84905020850     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00140     Document Type: Review

References (115)

1. Addolorato, G., Caputo, F., Capristo, E., Colombo, G., Gessa, G. L., and Gasbarrini, G. (2000). Ability of baclofen in reducing alcohol craving and intake: II-Preliminary clinical evidence. Alcohol. Clin. Exp. Res. 24, 67-71. doi: 10.1111/j.1530-0277.2000.tb04555.x
2. Addolorato, G., Caputo, F., Capristo, E., Domenicali, M., Bernardi, M., Janiri, L., et al. (2002b). Baclofen efficacy in reducing alcohol craving and intake-a preliminary double-blind randomised controlled study. Alcohol Alcohol. 37, 504-508. doi: 10.1093/alcalc/37.5.504
3. Addolorato, G., Caputo, F., Capristo, E., Janiri, L., Bernardi, M., Agabio, R., et al. (2002a). Rapid suppression of alcohol withdrawal syndrome by baclofen. Am. J. Med. 112, 226-229. doi: 10.1016/S0002-9343(01)01088-9
4. Addolorato, G., Leggio, L., Abenavoli, L., Agabio, R., Caputo, F., Capristo, E., et al. (2006). Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam. Am. J. Med. 119, 276.e13-276.e18. doi: 10.1016/j.amjmed.2005.08.042
5. Addolorato, G., Leggio, L., Abenavoli, L., DeLorenzi, G., Parente, A., Caputo, F., et al. (2003). Suppression of alcohol delirium tremens by baclofen administration: a case report. Clin. Neuropharmacol. 26, 258-262. doi: 10.1097/00002826-200309000-00010
6. Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Bedogni, G., Caputo, F., et al. (2011). Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol. Alcohol. 46, 312-317. doi: 10.1093/alcalc/agr017
7. Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., et al. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370, 1915-1922. doi: 10.1016/S0140-6736(07)61814-5
8. Agabio, R., Marras, P., Addolorato, G., Carpiniello, B., and Gessa, G. L. (2007). Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J. Clin. Psychopharmacol. 27, 319-320. doi: 10.1097/01.jcp.0000270079.84758.fe
9. Agabio, R., Preti, A., and Gessa, G. L. (2013). Efficacy and tolerability of baclofen in substance use disorders: a systematic review. Eur. Addict. Res. 19, 325-345. doi: 10.1159/000347055
10. Amato, L., Minozzi, S., and Davoli, M. (2011). Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst. Rev. 6:CD008537. doi: 10.1002/14651858.CD008537
11. Amato, L., Minozzi, S., Vecchi, S., and Davoli, M. (2010). Benzodiazepines for alcohol withdrawal. Cochrane Database Syst. Rev. 3:CD005063. doi: 10.1002/14651858.CD005063.pub3
12. Ameisen, O. (2005). Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 40, 147-150. doi: 10.1093/alcalc/agh130
13. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn, Text Revision: DSM-IV-TR. Washington, DC.
14. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. Arlington, VA.
15. Anstrom, K. K., Cromwell, H. C., Markowski, T., and Woodward, D. J. (2003). Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol. Clin. Exp. Res. 27, 900-908. doi: 10.1111/j.1530-0277.2003.tb04414.x
16. Arias, C., Mlewski, E. C., Molina, J. C., and Spear, N. E. (2009). Naloxone and baclofen attenuate ethanol's locomotor-activating effects in preweanling Sprague-Dawley rats. Behav. Neurosci. 123, 172-180. doi: 10.1037/a0014049
17. Bechtholt, A. J., and Cunningham, C. L. (2005). Ethanol-induced conditioned place preference is expressed through a ventral tegmental area dependent mechanism. Behav. Neurosci. 119, 213-223. doi: 10.1037/0735-7044.119.1.213
18. Besheer, J., Lepoutre, V., and Hodge, C. W. (2004). GABAB receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology 74, 358-366. doi: 10.1007/s00213-003-1769-3
19. Bettler, B., Kaupmann, K., Mosbacher, J., and Gassmann, M. (2004). Molecular structure and physiological functions of GABA(B) receptors. Physiol. Rev. 84, 835-867. doi: 10.1152/physrev.00036.2003
20. Boehm, S. L., Piercy, M. M., Bergstrom, H. C., and Phillips, T. J. (2002). Ventral tegmental area region governs GABAB receptor modulation of ethanol-stimulated activity in mice. Neuroscience 115, 185-200. doi: 10.1016/S0306-4522(02)00378-0
21. Bowery, N. G., Hudson, A. L., and Price, G. W. (1987). GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 20, 365-383. doi: 10.1016/0306-4522(87)90098-4
22. Broadbent, J., and Harless, W. E. (1999). Differential effects of GABAA and GABAB agonists on sensitization to the locomotor stimulant effects of ethanol in DBA/2 J mice. Psychopharmacology 141, 197-205. doi: 10.1007/s002130050825
23. Bucknam, W. (2007). Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 42, 158-160. doi: 10.1093/alcalc/agl091
24. Carai, M. A. M., Agabio, R., Addolorato, G., Gessa, G. L., and Colombo, G. (2005). "Baclofen: preclinical data," in Drugs for Relapse Prevention of Alcoholism, eds R. Spanagel and K. Mann (Basel: Birkäuser Verlag), 163-170.
25. Chen, K. S., Bullard, M. J., Chien, Y. Y., and Lee, S. Y. (1997). Baclofen toxicity in patients with severely impaired renal function. Ann. Pharmacother. 31, 1315-1320.
26. Chester, J. A., and Cunningham, C. L. (1999). Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol. Biochem. Behav. 63, 325-331. doi: 10.1016/S0091-3057(98)00253-6
27. Chick, J., and Nutt, D. J. (2012). Substitution therapy for alcoholism: time for a reappraisal? J. Psychopharmacol. 26, 205-212. doi: 10.1177/0269881111408463
28. Colombo, G., Agabio, R., Carai, M. A. M., Lobina, C., Pani, M., Reali, R., et al. (2000). Ability of baclofen in reducing alcohol intake and withdrawal severity: I-Preclinical evidence. Alcohol. Clin. Exp. Res. 24, 58-66. doi: 10.1111/j.1530-0277.2000.tb04554.x
29. Colombo, G., Serra, S., Brunetti, G., Atzori, G., Pani, M., Vacca, G., et al. (2002). The GABAB receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol. 37, 499-503. doi: 10.1093/alcalc/37.5.499
30. Colombo, G., Serra, S., Brunetti, G., Vacca, G., Carai, M. A. M., and Gessa, G. L. (2003a). Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend. 70, 105-108. doi: 10.1016/S0376-8716(02)00333-2
31. Colombo, G., Serra, S., Vacca, G., Carai, M. A. M., and Gessa, G. L. (2006). Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. Eur. J. Pharmacol. 550, 123-126. doi: 10.1016/j.ejphar.2006.08.052
32. Colombo, G., Vacca, G., Serra, S., Brunetti, G., Carai, M. A. M., and Gessa, G. L. (2003b). Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology 167, 221-224. doi: 10.1007/s00213-003-1397-y
33. Cott, J., Carlsson, A., Engel, J., and Lindqvist, M. (1976). Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn-Schmiedeberg's Arch. Pharmacol. 295, 203-209. doi: 10.1007/BF00505087
34. Couve, A., Calver, A. R., Fairfax, B., Moss, S. J., and Pangalos, M. N. (2004). Unravelling the unusual signalling properties of the GABAB receptor. Biochem. Pharmacol. 68, 1527-1536. doi: 10.1016/j.bcp.2004.06.036
35. Cryan, J. F., Kelly, P. H., Chaperon, F., Gentsch, C., Mombereau, C., Lingenhoehl, K., et al. (2004). Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J. Pharmacol. Exp. Ther. 310, 952-963. doi: 10.1124/jpet.104.066753
36. Daoust, M., Saligaut, C., Lhuintre, J. P., Moore, N., Flipo, J. L., and Boismare, F. (1987). GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol 4, 469-472. doi: 10.1016/0741-8329(87)90087-5
37. Dario, A., and Tomei, G. (2004). A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 27, 799-818. doi: 10.2165/00002018-200427110-00004
38. Dean, R. L., Eyerman, D., Todtenkopf, M. S., Turncliff, R. Z., Bidlack, J. M., and Deaver, D. R. (2011). Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacol. Biochem. Behav. 100, 530-537. doi: 10.1016/j.pbb.2011.10.019
39. de Beaurepaire, R. (2012). Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front. Psychiatry 3:103. doi: 10.3389/fpsyt.2012.00103
40. Dore, G. M., Lo, K., Juckes, L., Bezyan, S., and Latt, N. (2011). Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol Alcohol. 46, 714-720. doi: 10.1093/alcalc/agr131
41. Duke, A. N., Kaminski, B. J., and Weerts, E. M. (2014). Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. Addict. Biol. 19, 16-26. doi: 10.1111/j.1369-1600.2012.00448.x
42. Emson, P. C. (2007). "GABAB receptors: structure and function," in GABA and the Basal Ganglia, Progress in Brain Research, Vol. 160, eds J. M. Tepper, E. D. Abercrombie, and J. P. Bolam (Amsterdam: Elsevier), 43-57.
43. Evans, S. M., and Bisaga, A. (2009). Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol. Clin. Exp. Res. 33, 19-30. doi: 10.1111/j.1530-0277.2008.00805.x
44. File, S. E., Zharkovsky, A., and Gulati, K. (1991). Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology 30, 183-190. doi: 10.1016/0028-3908(91)90202-M
45. Flannery, B. A., Garbutt, J. C., Cody, M. W., Renn, W., Grace, K., Osborne, M., et al. (2004). Baclofen for alcohol dependence: a preliminary open-label study. Alcohol. Clin. Exp. Res. 28, 1517-1523. doi: 10.1097/01.ALC.0000141640.48924.14
46. Franck, J., and Jayaram-Lindström, N. (2013). Pharmacotherapy for alcohol dependence: status of current treatments. Curr. Opin. Neurobiol. 23, 692-699. doi: 10.1016/j.conb.2013.05.005
47. Froestl, W. (2010). Chemistry and pharmacology of GABAB receptor ligands. Adv. Pharmacol. 58, 19-62. doi: 10.1016/S1054-3589(10)58002-5
48. Garbutt, J. C., Kampov-Polevoy, A. B., Gallop, R., Kalka-Juhl, L., and Flannery, B. A. (2010). Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol. Clin. Exp. Res. 34, 1849-1857. doi: 10.1111/j.1530-0277.2010.01273.x
49. Gerkin, R., Curry, S. C., Vance, M. V., Sankowski, P. W., and Meinhart, R. D. (1986). First-order elimination kinetics following baclofen overdose. Ann. Emerg. Med. 15, 843-846. doi: 10.1016/S0196-0644(86)80388-2
50. Gorsane, M. A., Kebir, O., Hache, G., Blecha, L., Aubin, H. J., Reynaud, M., et al. (2012). Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates. Subst. Abuse 33, 336-349. doi: 10.1080/08897077.2012.663326
51. Hall, W., and Zador, D. (1997). The alcohol withdrawal syndrome. Lancet 349, 1897-1900. doi: 10.1016/S0140-6736(97)04572-8
52. Holstein, S. E., Dobbs, L., and Phillips, T. J. (2009). Attenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABAA, but not a GABAB, receptor agonist. Alcohol. Clin. Exp. Res. 33, 108-120. doi: 10.1111/j.1530-0277.2008.00817.x
53. Humeniuk, R. E., White, J. M., and Ong, J. (1993). The role of GABAB receptors in mediating the stimulatory effects of ethanol in mice. Psychopharmacology 111, 219-224. doi: 10.1007/BF02245527
54. Hwa, L. S., Chu, A., Levinson, S. A., Kayyali, T. M., DeBold, J. F., and Miczek, K. A. (2011). Persistent escalation of alcohol drinking in C57BL/6J mice with intermittent access to 20% ethanol. Alcohol. Clin. Exp. Res. 35, 1938-1947. doi: 10.1111/j.1530-0277.2011.01545.x
55. Hwa, L. S., Kalinichev, M., Haddouk, H., Poli, S., and Miczek, K. A. (2014). Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. Psychopharmacology 231, 333-343. doi: 10.1007/s00213-013-3245-z
56. Janak, P. H., and Gill, T. M. (2003). Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose. Alcohol 30, 1-7. doi: 10.1016/S0741-8329(03)00068-5
57. Knapp, D. J., Overstreet, D. H., and Breese, G. R. (2007). Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol. Clin. Exp. Res. 31, 582-595. doi: 10.1111/j.1530-0277.2007.00342.x
58. Krupitsky, E. M., Burakov, A. M., Ivanov, V. B., Krandashova, G. F., Lapin, I. P., Grinenko, A. J., et al. (1993). Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 33, 157-163. doi: 10.1016/0376-8716(93)90057-W
59. Lal, R., Sukbuntherng, J., Tai, E. H., Upadhyay, S., Yao, F., Warren, M. S., et al. (2009). Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J. Pharmacol. Exp. Ther. 330, 911-921. doi: 10.1124/jpet.108.149773
60. Lee, T. H., Chen, S. S., Su, S. L., and Yang, S. S. (1992). Baclofen intoxication: report of four cases and review of the literature. Clin. Neuropharmacol. 15, 56-62. doi: 10.1097/00002826-199202000-00008
61. Leggio, L., Garbutt, J. C., and Addolorato, G. (2010). Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol. Disord. Drug Targets 9, 33-44. doi: 10.2174/187152710790966614
62. Leggio, L., Kenna, G. A., and Swift, R. M. (2008). New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1106-1117. doi: 10.1016/j.pnpbp.2007.09.021
63. Leggio, L., Zywiak, W. H., McGeary, J. E., Edwards, S., Fricchione, S. R., Shoaff, J. R., et al. (2013). A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol. Biochem. Behav. 103, 784-791. doi: 10.1016/j.pbb.2012.11.013
64. Leite-Morris, K. A. (2004). The effects of ventral tegmental baclofen on ethanol-induced motor stimulation and sensitization in DBA/2 mice. Alcohol. Clin. Exp. Res. 28, 182A.
65. Leite-Morris, K. A., and Czachowski, C. L. (2006). Intra-ventral tegmental area microinjections of a GABA receptor agonist dose-dependently attenuate ethanol seeking in rats. Alcohol. Clin. Exp. Res. 30, 182A.
66. Leite-Morris, K. A., Misch, E. S., and Czachowski, C. L. (2008). Intra-VTA activation of GABA(B) receptors modulates accumbal dopamine during ethanol seeking behavior. Alcohol. Clin. Exp. Res. 32, 276A.
67. Liang, J. H., Chen, F., Krstew, E., Cowen, M. S., Carroll, F. Y., Crawford, D., et al. (2006). The GABAB receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 50, 632-639. doi: 10.1016/j.neuropharm.2005.11.011
68. Linsenbardt, D. N., and Boehm, S. L. (2013). Alterations in the rate of binge ethanol consumption: implications for preclinical studies in mice. Addict. Biol. doi: 10.1111/adb.12052. [Epub ahead of print].
69. Liu, J., and Wang, L. (2011). Baclofen for alcohol withdrawal. Cochrane Database Syst. Rev. 19:CD008502. doi: 10.1002/14651858.CD008502
70. Loi, B., Maccioni, P., Lobina, C., Carai, M. A. M., Gessa, G. L., Thomas, A. W., et al. (2013). Reduction of alcohol intake by the positive allosteric modulator of the GABAB receptor, rac-BHFF, in alcohol-preferring rats. Alcohol 47, 69-73. doi: 10.1016/j.alcohol.2012.11.002
71. Lyon, J. E., Khan, R. A., Gessert, C. E., Larson, P. M., and Renier, C. M. (2011). Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J. Hosp. Med. 6, 474-479. doi: 10.1002/jhm.928
72. Maccioni, P., Bienkowski, P., Carai, M. A. M., Gessa, G. L., and Colombo, G. (2008a). Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend. 95, 284-287. doi: 10.1016/j.drugalcdep.2008.02.006
73. Maccioni, P., Carai, M. A. M., Kaupmann, K., Guery, S., Froestl, W., Leite-Morris, K. A., et al. (2009). Reduction of alcohol's reinforcing and motivational properties by the positive allosteric modulator of the GABAB receptor, BHF177, in alcohol-preferring rats. Alcohol. Clin. Exp. Res. 33, 1749-1756. doi: 10.1111/j.1530-0277.2009.01012.x
74. Maccioni, P., Fantini, N., Froestl, W., Carai, M. A. M., Gessa, G. L., and Colombo, G. (2008b). Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783-comparison with the effect of the GABAB receptor direct agonist, baclofen. Alcohol. Clin. Exp. Res. 32, 1558-1564. doi: 10.1111/j.1530-0277.2008.00725.x
75. Maccioni, P., Pes, D., Orrù, A., Froestl, W., Gessa, G. L., Carai, M. A. M., et al. (2007). Reducing effect of the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in alcohol-preferring rats. Psychopharmacology 193, 171-178. doi: 10.1007/s00213-007-0776-1
76. Maccioni, P., Serra, S., Vacca, G., Orrù, A., Pes, D., Agabio, R., et al. (2005). Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol 36, 161-168. doi: 10.1016/j.alcohol.2005.08.003
77. Maccioni, P., Thomas, A. W., Carai, M. A. M., Gessa, G. L., Malherbe, P., and Colombo, G. (2010). The positive allosteric modulator of the GABAB receptor, rac-BHFF, suppresses alcohol self-administration. Drug Alcohol Depend. 109, 96-103. doi: 10.1016/j.drugalcdep.2009.12.019
78. Maccioni, P., Zaru, A., Loi, B., Lobina, C., Carai, M. A. M., Gessa, G. L., et al. (2012). Comparison of the effect of the GABAB receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in three different lines of alcohol-preferring rats. Alcohol. Clin. Exp. Res. 36, 1748-1766. doi: 10.1111/j.1530-0277.2012.01782.x
79. Malherbe, P., Masciadri, R., Norcross, R. D., Knoflach, F., Kratzeisen, C., Zenner, M.-T., et al. (2008). Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Br. J. Pharmacol. 154, 797-811. doi: 10.1038/bjp.2008.135
80. Markou, A., Weiss, F., Gold, L. H., Caine, S. B., Schulteis, G., and Koob, G. F. (1993). Animal models of drug craving. Psychopharmacology 112, 163-182. doi: 10.1007/BF02244907
81. Martin-Fardon, R., and Weiss, F. (2013). Modeling relapse in animals. Curr. Top. Behav. Neurosci. 13, 403-432. doi: 10.1007/978-3-642-28720-6_202
82. Mayo-Smith, M. F. (1997). Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. J. Am. Med. Assoc. 278, 144-151. doi: 10.1001/jama.1997.03550020076042
83. Moore, E. M., and Boehm, S. L. (2009). Site-specific microinjection of baclofen into the anterior ventral tegmental area reduces binge-like ethanol intake in male C57BL/6J mice. Behav. Neurosci. 123, 555-563. doi: 10.1037/a0015345
84. Nasti, J. J., and Brakoulias, V. (2011). Chronic baclofen abuse and withdrawal delirium. Aust. N.Z. J. Psychiatry 45, 86-87. doi: 10.3109/00048674.2010.524622
85. Nutt, D. J., King, L. A., and Phillips, L. D. (2010). Drug harms in the UK: a multicriteria decision analysis. Lancet 376, 1558-1565. doi: 10.1016/S0140-6736(10)61462-6
86. Orrù, A., Fujani, D., Cassina, C., Conti, M., Di Clemente, A., and Cervo, L. (2012). Operant, oral alcoholic beer self-administration by C57BL/6J mice: effect of BHF177, a positive allosteric modulator of GABAB receptors. Psychopharmacology 222, 685-700. doi: 10.1007/s00213-012-2672-6
87. Orrù, A., Lai, P., Lobina, C., Maccioni, P., Piras, P., Scanu, L., et al. (2005). Reducing effect of the positive allosteric modulators of the GABAB receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats. Eur. J. Pharmacol. 525, 105-111. doi: 10.1016/j.ejphar.2005.10.005
88. Pastor, A., Jones, D. M., and Currie, J. (2012). High-dose baclofen for treatment-resistant alcohol dependence. J. Clin. Psychopharmacol. 32, 266-268. doi: 10.1097/JCP.0b013e31824929b2
89. Pastor, A., Lloyd-Jones, M., and Currie, J. (2013). Reply to Dr. Rolland et al. re: "Baclofen for alcohol-dependence: anticraving or partial substitution?." J. Clin. Psychopharmacol. 33, 281-282. doi: 10.1097/JCP.0b013e3182897431
90. Paterson, N. E., Vlachou, S., Guery, S., Kaupmann, K., Froestl, W., and Markou, A. (2008). Positive modulation of GABAB receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J. Pharmacol. Exp. Ther. 326, 306-314. doi: 10.1124/jpet.108.139204
91. Perry, H. E., Wright, R. O., Shannon, M. W., and Woolf, A. D. (1998). Baclofen overdose: drug experimentation in a group of adolescents. Pediatrics 101, 1045-1048. doi: 10.1542/peds.101.6.1045
92. Peters, S., Slattery, D. A., Flor, P. J., Neumann, I. D., and Reber, S. O. (2013). Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice. Addict. Biol. 18, 66-77. doi: 10.1111/adb.12001
93. Petry, N. M. (1997). Benzodiazepine-GABA modulation of concurrent ethanol and sucrose reinforcement in the rat. Exp. Clin. Psychopharmacol. 5, 183-194. doi: 10.1037/1064-1297.5.3.183
94. Quintanilla, M. E., Perez, E., and Tampier, L. (2008). Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats. Addict. Biol. 13, 326-336. doi: 10.1111/j.1369-1600.2008.00102.x
95. Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., and Patra, J. (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373, 2223-2233. doi: 10.1016/S0140-6736(09)60746-7
96. Rigal, L., Alexandre-Dubroeucq, C., de Beaurepaire, R., Le Jeunne, C., and Jaury, P. (2012). Abstinence and "low-risk" consumption 1 year after the initiation of high-dose baclofen: a retrospective study among "high-risk" drinkers. Alcohol Alcohol. 47, 439-442. doi: 10.1093/alcalc/ags028
97. Rolland, B., Bordet, R., and Cottencin, O. (2012). Alcohol-dependence: the current French craze for baclofen. Addiction 107, 848-849. doi: 10.1111/j.1360-0443.2011.03752.x
98. Rolland, B., Bordet, R., Deheul, S., and Cottencin, O. (2013). Baclofen for alcohol-dependence: anticraving or partial substitution? J. Clin. Psychopharmacol. 33, 280-281. doi: 10.1097/JCP.0b013e3182860e84
99. Schuckit, M. A. (2009). Alcohol-use disorders. Lancet 373, 492-501. doi: 10.1016/S0140-6736(09)60009-X
100. Shen, E. H., Dorow, J., Harland, R., Burkhart-Kasch, S., and Phillips, T. J. (1998). Seizure sensitivity and GABAergic modulation of ethanol sensitivity in selectively bred FAST and SLOW mouse lines. J. Pharmacol. Exp. Ther. 287, 606-615.
101. Smith, B. R., Boyle, A. E. L., and Amit, Z. (1999). The effects of GABAB agonist baclofen on the temporal and structural characteristics of ethanol intake. Alcohol 17, 231-240. doi: 10.1016/S0741-8329(98)00053-6
102. Smith, C. R., LaRocca, N. G., Giesser, B. S., and Scheinberg, L. C. (1991). High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 41, 1829-1831. doi: 10.1212/WNL.41.11.1829
103. Stallings, W., and Schrader, S. (2007). Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review. J. Okla State Med. Assoc. 100, 354-360.
104. Stromberg, M. F. (2004). The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol. Biochem. Behav. 78, 743-750. doi: 10.1016/j.pbb.2004.05.006
105. Tanchuck, M. A., Yoneyama, N., Ford, M. M., Fretwell, A. M., and Finn, D. A. (2011). Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. Alcohol 45, 33-44. doi: 10.1016/j.alcohol.2010.07.009
106. Tiffany, S. T., and Wray, J. M. (2012). The clinical significance of drug craving. Ann. N.Y. Acad. Sci. 1248, 1-17. doi: 10.1111/j.1749-6632.2011.06298.x
107. Tzschentke, T. M. (2007). Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 12, 227-462. doi: 10.1111/j.1369-1600.2007.00070.x
108. van Amsterdam, J. G., Brunt, T. M., McMaster, M. T., and Niesink, R. J. (2012). Possible long-term effects of ?-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci. Biobehav. Rev. 36, 1217-1227. doi: 10.1016/j.neubiorev.2012.02.002
109. Villas Boas, G. R., Zamboni, C. G., Peretti, M. C., Correia, D., Rueda, A. V., Camarini, R., et al. (2012). GABAB receptor agonist only reduces ethanol drinking in light-drinking mice. Pharmacol. Biochem. Behav. 102, 233-240. doi: 10.1016/j.pbb.2012.04.011
110. Vlachou, S., and Markou, A. (2010). GABAB receptors in reward processes. Adv. Pharmacol. 58, 315-371. doi: 10.1016/S1054-3589(10)58013-X
111. Walker, B. M., and Koob, G. F. (2007). The ?-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol. Clin. Exp. Res. 31, 11-18. doi: 10.1111/j.1530-0277.2006.00259.x
112. Weiss, F., and Porrino, L. J. (2002). Behavioral neurobiology of alcohol addiction: recent advances and challenges. J. Neurosci. 22, 3332-3337.
113. Weisshaar, G. F., Hoemberg, M., Benderm, K., Bangen, U., Herkenrath, P., Eifinger, F., et al. (2012). Baclofen intoxication: a "fun drug" causing deep coma and nonconvulsive status epilepticus-a case report and review of the literature. Eur. J. Pediatr. 171, 1541-1547. doi: 10.1007/s00431-012-1780-y
114. Wise, R. A., and Bozarth, M. A. (1987). A psychomotor stimulant theory of addiction. Psychol. Rev. 94, 469-492. doi: 10.1037/0033-295X.94.4.469
115. Wuis, E. W., Dirks, M. J., Termond, E. F., Vree, T. B., and Van der Kleijn, E. (1989). Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur. J. Clin. Pharmacol. 37, 181-184. doi: 10.1007/BF00558228